In-Vivo Imaging - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The In-Vivo imaging market size was valued at USD 1.21 billion in 2025 and is estimated to grow from USD 1.34 billion in 2026 to reach USD 2.19 billion by 2031, at a CAGR of 10.36% during the forecast period (2026-2031). This report is segmented by Product (Systems and Reagents), Techniques (Radioisotopes, Biomarkers, Luminescent Proteins, and Others), End User (Hospitals and Clinics, Imaging Centers, Research Organizations, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Global In-Vivo Imaging Market Trends and Insights

Expansion of Biopharma R&D Pipelines and Preclinical Study Complexity

Biopharma research activity remained resilient through 2025, and global clinical and preclinical pipeline volumes grew at high-single-digit annual rates from 2020. The in-vivo imaging market gains from this activity because oncology, gene therapy, and cell therapy programs need several preclinical endpoints. Imaging supports pharmacokinetics, biodistribution, and repeated disease monitoring within the same animal cohort. IQVIA reported 79 novel active substances launched globally in 2025 and expects an annual average of 70-80 through 2030. China’s larger pipeline contribution is also increasing demand for preclinical imaging capacity in Asian contract research organizations. More complex programs can require more imaging sessions per candidate, which supports demand even when pipeline volumes vary.

Shift Toward Non-Invasive Longitudinal Imaging

Non-invasive longitudinal imaging aligns with the 3Rs principles reflected in European animal-research rules and the U.S. Animal Welfare Act. The in-vivo imaging market, therefore, benefits from methods that allow repeated, minimally stressful imaging in the same animal. Optical bioluminescence, micro-MRI, and photoacoustic systems can support these repeated assessments. A 2025 peer-reviewed review identified fluorescence and bioluminescence as widely used longitudinal tools because of their ease of use, accessible instrumentation, and range of applications. Longitudinal designs can reduce animal numbers per study while increasing the number of sessions for each surviving animal. This pattern can protect probe and consumable demand even as study cohorts become smaller.

High Capital, Maintenance, and Qualification Costs

Capital cost remains a major barrier to adoption outside North America and Europe. A multimodal suite that combines PET/SPECT, micro-MRI, and optical imaging can require multi-million-dollar investment before qualification activities. Installation, operational, and performance qualification add to the system cost. Contract research organizations also need documentation that meets sponsor-specific good laboratory practice requirements. These needs create costs that equipment prices alone do not show. Subscription and per-scan models respond to the constraint, although use remains concentrated among larger organizations that can manage these contracts.

Other drivers and restraints analyzed in the detailed report include:

• Adoption of Multimodal Hybrid Imaging
• Rising Demand for Quantitative Translational Biomarkers
• Stringent Preclinical and Animal-Research Regulations

Segment Analysis

Systems held 62.48% of the in-vivo imaging market share in 2025, making them the leading product group. The category includes optical imaging systems, nuclear imaging systems, micro-MRI, micro-ultrasound, photoacoustic imaging systems, and others. Optical systems retained a leading position within systems because bioluminescence and fluorescence workflows have been widely deployed. They offer lower per-session consumable costs and simpler operating requirements than nuclear imaging or MRI alternatives. Nuclear imaging systems remain important for quantitative PET and SPECT readouts in radiopharmaceutical biodistribution studies. Micro-MRI and micro-ultrasound meet more specialized needs for soft-tissue contrast and real-time cardiovascular phenotyping.

Reagents are forecast to grow at a 10.89% CAGR through 2031, supported by their recurring role in imaging workflows. The group includes optical imaging reagents, nuclear imaging reagents, MRI contrast agents, ultrasound contrast agents, CT contrast agents, and others. Nuclear reagents retain an established role in PET and SPECT studies, including work with 18F-FDG, 68Ga-labeled peptides, and 99mTc-based compounds. Optical probes are being developed through near-infrared fluorophores, activatable probes, and self-illuminating luciferase systems. These products can extend imaging depth, reduce autofluorescence background, and enable multiplexed molecular readouts. A 2025 review noted that shared optical imaging core facilities supported by NIH S10 grants and comparable European mechanisms can create continuing demand for consumable reagents.

Complete Report Scope:

• By Product
  • Systems
    • Optical Imaging Systems
    • Nuclear Imaging Systems
    • Micro-MRI
    • Micro-Ultrasound
    • Photoacoustic Imaging Systems
    • Others
  • Reagents
    • Optical Imaging Reagents
    • Nuclear Imaging Reagents
    • MRI Contrast Agents
    • Ultrasound Contrast Agents
    • CT Contrast Agents
    • Others
• By Techniques
  • Radioisotopes
  • Biomarkers
  • Luminescent Proteins
  • Others
• By End User
  • Hospitals and Clinics
  • Imaging Centers
  • Research Organizations
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 36.16% of the 2026 in-vivo imaging market revenue, supported by the United States’ concentration of publicly funded research centers, pharmaceutical and biotechnology research campuses, and contract research organizations. Canada contributes a growing base in oncology and neuroscience research. Mexico remains an earlier-stage national market. Revenue generation in the region is shifting toward imaging-as-a-service and per-scan models. This shift moves more revenue from equipment sales toward integrated service providers. The FDA Biomarker Qualification Program supports demand for platforms that can produce quantitative data suitable for submissions.

Asia-Pacific is forecast to grow at a 13.51% CAGR from 2026 to 2031, nearly 3 percentage points above the global rate. China is adding preclinical research capacity and is a central demand center in the region. The Chinese government announced funding for 5 new high-resolution micro-CT scanner development programs in 2025, supporting domestic manufacturing capability. Japan’s AMED allocated JPY 8.4 billion, equivalent to USD 56 million, for regenerative medicine imaging programs in 2025. India, South Korea, and Australia also add research infrastructure and academic-industry collaborations. This broad base makes the region’s in-vivo imaging market opportunity wider than China alone.

Europe holds the second position in the in-vivo imaging market, with Germany, the United Kingdom, and France supporting multi-institutional imaging networks. Germany’s Helmholtz Association and United Kingdom Medical Research Council-funded networks help stabilize public-sector procurement. EU Directive 2010/63/EU encourages longitudinal study design while increasing compliance requirements for operators. The Middle East, Africa, and South America remain at earlier stages of adoption. GCC sovereign health investment funds are beginning to support biomedical research infrastructure. Brazil’s regulatory alignment with FDA standards could support São Paulo research clusters as Latin American hubs for imaging-intensive preclinical work. The in-vivo imaging market could benefit if these clusters gain wider access to qualified equipment, radiopharmacy support, and specialized operators.

List of Companies Covered in this Report:

• Aspect Imaging Ltd.
• Biospace Lab
• Bruker
• CMR Naviscan
• FUJIFILM
• GE Healthcare
• Guerbet
• Hitachi
• Koninklijke Philips
• LI-COR, Inc.
• Mediso
• MILabs
• Miltenyi Biotec
• MR Solutions
• PerkinElmer
• SCANCO Medical AG
• Siemens Healthineers
• Takara Bio
• Thermo Fisher Scientific
• Trifoil Imaging

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support